Proliferative vitreoretinopathy Pipeline

DelveInsight reports that over 3 key companies are actively engaged in developing more than 3 therapies for the treatment of Proliferative Vitreoretinopathy (PVR).

Proliferative vitreoretinopathy Overview:

Proliferative Vitreoretinopathy (PVR) is a rare but serious eye disorder that can lead to severe vision loss or blindness. It most often arises as a complication following retinal detachment surgery or as a result of open globe injuries (ocular trauma).

In PVR, retinal cells abnormally proliferate and form scar tissue, which contracts and causes the retina to detach again. Currently, there are no approved therapies for this condition. PVR is responsible for about 75% of complications after retinal detachment and occurs in 5–10% of patients undergoing retinal detachment surgery, as well as in up to 50% of cases involving open globe injuries.

Download our report @ https://www.delveinsight.com/report-store/proliferative-vitreoretinopathy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

“Proliferative vitreoretinopathy Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Proliferative vitreoretinopathy Therapeutics Market.

Key Takeaways from the Proliferative vitreoretinopathy Pipeline Report

• DelveInsight’s Proliferative Vitreoretinopathy (PVR) pipeline report highlights a highly active landscape, with 80+ companies engaged in the development of more than 100 pipeline therapies for PVR treatment.

• Aldeyra Therapeutics is progressing ADX-2191, a preservative-free intravitreal methotrexate formulation, for PVR prevention. The FDA granted Orphan Drug Designation for ADX-2191 in 2018. Results from the Phase 3 GUARD trial showed the drug was statistically superior to historical controls in preventing retinal detachment and demonstrated numerical benefits over routine surgical care across multiple secondary endpoints. Importantly, it was well-tolerated with no serious adverse events. In 2023, Aldeyra announced plans for a Type C meeting with the FDA to discuss completing clinical development for ADX-2191 in PVR prevention.

• Notable companies in the PVR space include Aldeyra Therapeutics, Tetra Bio-Pharma, Aviceda Therapeutics, and others, all working to expand treatment options.

• Promising candidates in the pipeline include ADX-2191, PPP-003, among others.

Proliferative vitreoretinopathy Pipeline Analysis

The Proliferative vitreoretinopathy pipeline insights report 2025, provides insights into:

• Provides comprehensive insights into key companies developing therapies in the Proliferative vitreoretinopathy Market.

• Categorizes Proliferative vitreoretinopathy therapeutic companies by development stage: early, mid, and late-stage.

• Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

• Reviews emerging Proliferative vitreoretinopathy drugs under development based on:

  • Stage of development

  • Proliferative vitreoretinopathy Route of administration

  • Target receptor

  • Monotherapy vs. combination therapy

  • Proliferative vitreoretinopathy Mechanism of action

  • Molecular type

• Offers detailed analysis of:

  • Company-to-company and company-academia collaborations

  • Proliferative vitreoretinopathy Licensing agreements

  • Funding and investment activities supporting future Proliferative vitreoretinopathy market advancement.

Request for a sample report @ https://www.delveinsight.com/sample-request/proliferative-vitreoretinopathy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Proliferative vitreoretinopathy Emerging Drugs

• ADX-2191: Aldeyra Therapeutics

ADX-2191, an intravitreal methotrexate formulation, has been granted Orphan Drug Designation for the prevention of Proliferative Vitreoretinopathy (PVR). Its therapeutic benefit is believed to arise from inhibiting abnormal retinal cell proliferation and activity, thereby reducing the retinal scarring characteristic of PVR. Aldeyra also holds an exclusive license for specific patents related to the use of ADX-2191 in PVR prevention.

• PPP-003: Tetra Bio-Pharma

PPP003 (HU308), a synthetic cannabinoid in preclinical development as an ophthalmic therapy, has received Orphan Drug Designation from the U.S. FDA for the prevention of Proliferative Vitreoretinopathy (PVR).

Proliferative vitreoretinopathy Companies

More than 3 key companies are actively developing therapies for Proliferative Vitreoretinopathy (PVR), with Aldeyra Therapeutics leading the field as its drug candidates have progressed to the most advanced stage, Phase III.

DelveInsight’s report covers around 100+ products under different phases of Proliferative vitreoretinopathy clinical trials like

• Proliferative vitreoretinopathy Late stage Therapies (Phase III)

• Proliferative vitreoretinopathy Mid-stage Therapies (Phase II)

• Proliferative vitreoretinopathy Early-stage Therapies (Phase I)

• Proliferative vitreoretinopathy Pre-clinical and Proliferative vitreoretinopathy Discovery stage Therapies

• Proliferative vitreoretinopathy Discontinued & Inactive Therapies

Proliferative vitreoretinopathy pipeline report provides the Proliferative vitreoretinopathy therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

Proliferative vitreoretinopathy Products have been categorized under various Molecule types such as

• Monoclonal antibody

• Small molecule

• Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Proliferative vitreoretinopathy Therapies and Key Proliferative vitreoretinopathy Companies: Proliferative vitreoretinopathy Clinical Trials and recent advancements

Proliferative vitreoretinopathy Pipeline Therapeutic Assessment

• Proliferative vitreoretinopathy Assessment by Product Type

• Proliferative vitreoretinopathy By Stage

• Proliferative vitreoretinopathy Assessment by Route of Administration

• Proliferative vitreoretinopathy Assessment by Molecule Type

Download Proliferative vitreoretinopathy Sample report to know in detail about the Proliferative vitreoretinopathy treatment market @ Proliferative vitreoretinopathy Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Proliferative vitreoretinopathy Current Treatment Patterns

4. Proliferative vitreoretinopathy – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Proliferative vitreoretinopathy Late-Stage Products (Phase-III)

7. Proliferative vitreoretinopathy Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Proliferative vitreoretinopathy Discontinued Products

13. Proliferative vitreoretinopathy Product Profiles

14. Proliferative vitreoretinopathy Key Companies

15. Proliferative vitreoretinopathy Key Products

16. Dormant and Discontinued Products

17. Proliferative vitreoretinopathy Unmet Needs

18. Proliferative vitreoretinopathy Future Perspectives

19. Proliferative vitreoretinopathy Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Proliferative vitreoretinopathy Pipeline Reports Offerings

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/